{
    "clinical_study": {
        "@rank": "74040", 
        "arm_group": [
            {
                "arm_group_label": "Progression-free survival&Concurrent chemoradiotherapy", 
                "arm_group_type": "Experimental", 
                "description": "The first day of radiotherapy given pemetrexed(Powder for Injection) 500mg/m2 + cisplatin(Powder for Injection) 75mg/m2, two cycles of chemotherapy given during radiotherapy; then continue to give two cycles of consolidation chemotherapy,  21 days as a cycle.\nIntensity-modulated radiation therapy(IMRT),5000cGy\uff5e6000cGy/5\uff5e6W."
            }, 
            {
                "arm_group_label": "Progression-free survival&sequential chemoradiotherapy", 
                "arm_group_type": "Active Comparator", 
                "description": "Patients received adjuvant chemotherapy for four cycles,pemetrexed(Powder for Injection) 500mg/m2 + cisplatin(Powder for Injection) 75mg/m2,  21 days as a cycle.Then accept the Intensity-modulated radiation therapy(IMRT),5000cGy\uff5e6000cGy/5\uff5e6W."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study  compares   chemoradiation and sequential chemoradiation about\n      Lung adenocarcinoma patients with postoperative in pN2 and then   determines  which\n      therapeutic method is better for the patients."
        }, 
        "brief_title": "Comparative Study of Chemoradiation and Sequential Chemoradiation About Lung Adenocarcinoma Patients With Postoperative in pN2", 
        "completion_date": {
            "#text": "January 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Lung Adenocarcinoma Patients With Postoperative in pN2", 
        "condition_browse": {
            "mesh_term": [
                "Adenocarcinoma", 
                "Lung Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Clinical diagnosis of Lung adenocarcinoma\n\n          -  Postoperative staging pN2 period\n\n          -  Voluntary participation and informed consent\n\n          -  Age \u2265 18 years old, male or female, within six months of weight loss of less\n               than 10%, can tolerate radiotherapy\n\n          -  performance status( PS) score 0-2.\n\n          -  Hemoglobin \u2265 80 g / L, white blood cell  \u2265 4 \u00d7 109 / L, platelets \u2265 100 \u00d7 109 / L.\n\n          -  Liver function: alanine aminotransferase (ALAT), aspartate transaminase (ASAT) <upper\n             limit of normal (ULN) of 1.5 times, bilirubin <1.5 \u00d7 ULN.\n\n          -  Renal function: serum creatinine <1.5 \u00d7 ULN.\n\n          -  Compliance, and can be regular follow-up, voluntary compliance with study\n             requirements\n\n        Exclusion Criteria:\n\n          -  Do not meet the inclusion criteria\n\n          -  There is evidence of distant metastases\n\n          -  Suffered from other malignancies in five years\n\n          -  Within the past January subjects received other drug trials\n\n          -  Having serious allergies or idiosyncratic persons, such as you can not use folic\n             acid, dexamethasone, vitamin B12 patients\n\n          -  Severe lung or heart disease, a history\n\n          -  Refuses or is unable to sign informed consent to participate in trials\n\n          -  The abuse of drugs or alcohol addicts.\n\n          -  Patients with difficult to control bacterial, viral, fungal infections\n\n          -  Having a personality or mental disorders, without civil capacity or restricted civil\n             capacity.\n\n          -  Being pregnant or lactating women."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 2, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02132143", 
            "org_study_id": "LH-2014-XW"
        }, 
        "intervention": [
            {
                "arm_group_label": "Progression-free survival&Concurrent chemoradiotherapy", 
                "description": "For concurrent chemoradiotherapy, the intensity-modulated radiation therapy(IMRT)will be given at the first day of therapy,total dose of 5000cGy\uff5e6000cGy/5-6 Weeks.", 
                "intervention_name": "intensity-modulated radiation", 
                "intervention_type": "Radiation"
            }, 
            {
                "arm_group_label": "Progression-free survival&sequential chemoradiotherapy", 
                "description": "For sequential chemoradiotherapy,the intensity-modulated radiation will(IMRT) will be given when patients received adjuvant chemotherapy for four cycles,total dose of 5000cGy\uff5e6000cGy/5-6 Weeks.", 
                "intervention_name": "intensity-modulated radiation", 
                "intervention_type": "Radiation"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Lung adenocarcinoma", 
            "Concurrent chemoradiotherapy", 
            "Sequential chemoradiotherapy", 
            "Progression-free survival"
        ], 
        "lastchanged_date": "May 6, 2014", 
        "location": {
            "contact": {
                "email": "linhui33266@sina.com", 
                "last_name": "Hui Lin", 
                "phone": "8613878133266"
            }, 
            "facility": {
                "address": {
                    "city": "Nanning Shi", 
                    "country": "China", 
                    "zip": "530021"
                }, 
                "name": "The People's Hospital of Guangxi Zhuang Autonomous Region"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "other_outcome": {
            "description": "06/01/2014-06/01/2015", 
            "measure": "side-effect", 
            "safety_issue": "Yes", 
            "time_frame": "one year"
        }, 
        "overall_contact": {
            "email": "linhui33266@sina.com", 
            "last_name": "Hui Lin, Doctor", 
            "phone": "8613878133622"
        }, 
        "overall_contact_backup": {
            "email": "yyvsyy6912@163.com", 
            "last_name": "Jiao Yang, Master", 
            "phone": "8613707872959"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Ministry of Health", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "01/01/2014-06/01/2016", 
            "measure": "progression-free survival", 
            "safety_issue": "Yes", 
            "time_frame": "two and a half years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02132143"
        }, 
        "responsible_party": {
            "investigator_affiliation": "People's Hospital of Guangxi", 
            "investigator_full_name": "Hui Lin", 
            "investigator_title": "The president of the People's Hospital of Guangxi", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": {
            "description": "01/01/2014-01/01-2016", 
            "measure": "Overall survival", 
            "safety_issue": "Yes", 
            "time_frame": "two and a half years"
        }, 
        "source": "People's Hospital of Guangxi", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hui Lin", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}